Sep 06, 2023 / 12:45PM GMT
Mohit Bansal - Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Good morning. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I'm very happy to start with Regeneron Pharmaceuticals today.
We have Marion McCourt, Head of Commercial at Regeneron, and Ryan Crowe, Head of Investor Relations. Thank you very much for joining us. Over to you, Ryan.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Thanks, Mohit, and it's great to be here. I always love coming to this conference. It's our second year in a row here, and I'm very excited to be here again.
I'd like to remind you that our remarks today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found on Regeneron's SEC filings.
Regeneron does not undertake any obligation to update any forward
Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript
Sep 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers